Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dark, Then Dawn: ANDA Workload Approaching Steady State After 2014 Eruption

Executive Summary

FDA Office of Generic Drugs' output is beginning to compete with, rather than be overwhelmed by, sponsors' input.

Advertisement

Related Content

Generic Drug Review: US FDA Approves More ANDAs Than It Receives For First Time Since Early 2016
Generic Drug Review At US FDA: Has Submission Rush Ended Or Just Paused?
ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System
ANDA Submission Wave Continues; Is A Crest Near?
GDUFA Negotiations Shift To 'Tiered' Fee Models
ANDA User Fees Offer Sponsor Relief, But More Facility Pain
FDA Meets ANDA Backlog Goal Early, Still Doesn't Feel Out Of Woods

Topics

Advertisement
UsernamePublicRestriction

Register

PS057539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel